Target intelligence / Profile preview

Tetanus neurotoxin (TeNT)

Target
TeNT
Molecular classification
Bacterial toxin, Zinc metalloprotease, AB-type toxin
01

Overview

Tetanus neurotoxin (TeNT), also known as tetanospasmin, is an extremely potent protein toxin produced by the bacterium Clostridium tetani and is the causative agent of tetanus (StatPearls, 2023). The toxin is a 150 kDa protein composed of a heavy chain (100 kDa) responsible for receptor binding and translocation, and a light chain (50 kDa) that functions as a zinc-dependent metalloprotease (UniProt P04958). TeNT enters the peripheral nervous system and undergoes retrograde axonal transport to reach the central nervous system, where it specifically cleaves synaptobrevin-2 (VAMP2) in inhibitory interneurons (PubMed, PMC7076335). This cleavage prevents the release of inhibitory neurotransmitters like GABA and glycine, leading to the characteristic muscle rigidity and spasms associated with the disease. In clinical practice, the toxin is inactivated with formaldehyde to create tetanus toxoid, which is the primary antigenic component in vaccines used to elicit protective neutralizing antibodies (CDC, 2022). Therapeutic management involves both active immunization with the toxoid and passive immunization with tetanus immune globulin to neutralize the toxin before it can bind to neuronal membranes.

Other names
TetanospasminTetanus toxinTeLTetXTetanus toxoid
02

Mechanism of action

Tetanus toxoid serves as an antigen to induce active immunity by stimulating the production of neutralizing IgG antibodies that bind to the toxin's C-terminal binding domain, preventing neuronal entry. Tetanus immune globulin provides passive immunity by directly neutralizing circulating toxin before it can bind to nerve endings.

03

Biological functions

Proteolysis of VAMP2/synaptobrevin-2Inhibition of inhibitory neurotransmitter releaseRetrograde axonal transportZinc-dependent endopeptidase activity
04

Disease associations

TetanusLockjawNeonatal tetanus
05

Safety considerations

Injection site reactions (erythema, induration)Arthus-type hypersensitivity reactionsBrachial neuritisAnaphylaxisGuillain-Barré syndrome (rare association)
06

Interacting drugs

Tetanus toxoid

5 more in the full profile.

07

Biomarkers

Anti-tetanus IgG antibody titer

Beyond the preview

Go deeper on Tetanus neurotoxin (TeNT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tetanus neurotoxin (TeNT).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call